| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $80.1M | — | +23.2% |
| R&D Expense | $9.0M | — | -28.4% |
| SG&A Expense | $43.1M | — | +0.3% |
| Operating Income | -$6.6M | — | +70.2% |
| Income Tax | $0 | — | — |
| Net Income | -$25.2M | — | +37.7% |
| EPS (Basic) | -$0.10 | — | +52.4% |
| EPS (Diluted) | -$0.10 | — | +52.4% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $156.2M | -7.0% | +36.2% |
| Accounts Receivable | $132.4M | -5.6% | +62.8% |
| Inventory | $104.2M | -0.9% | +4.9% |
| Current Assets | $459.5M | -0.7% | +44.1% |
| Total Assets | $462.5M | -0.7% | +42.7% |
| Current Liabilities | $300.4M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$27.7M | — | -22.5% |
| Capital Expenditures | $189K | — | — |
| Investing Cash Flow | -$189K | — | — |
| Financing Cash Flow | $16.2M | — | +316.2% |
| Free Cash Flow | -$27.9M | — | -23.3% |
| +10.8% |
| Total Liabilities | $770.5M | +0.3% | +2.7% |
| Stockholders' Equity | -$307.9M | -2.0% | +27.8% |